Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors provide an approach to clinical supervision that can mitigate the perils and ...

The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

The landscape for genetically modified organisms is changing, thanks to sharp increases in the amounts and numbers of chemical herbicides applied to GM crops and the classification of two of the mo ...

The benefits of women’s health research haven’t been limited to women. But actions by the Trump administration threaten to dismantle the hard-won progress in this area.

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as pharmacotherapies targeting the associated liver and cardiovascular ...

In 1979, China implemented the one-child family policy, which restricts many couples to a single offspring. The authors describe the policy's success in slowing population growth as well as its adv ...

A small-molecule drug proves its mettle in the treatment of spinal muscular atrophy, a disease amenable to intervention at the pre-mRNA level.

A man from rural India presented with redness and blurry vision in one eye. Examination was notable for panuveitis and a live worm in the posterior segment; the worm was removed in a pars plana vit ...

To the Editor: Cederholm and Bosaeus (July 11 issue)1 propose three causal subtypes of malnutrition: disease-related with and without underlying inflammation and “starvation due to inadequate ...

An 80-year-old woman presented with a 3-day history of abdominal pain. Imaging revealed numerous small gallstones in the gallbladder and cystic duct, consistent with cholecystitis.

To the Editor: The trial by the BALANCE (Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness) investigators (March 13/20 issue)1 provides valuable insights for clinicians, suppo ...

Neoadjuvant trials introduce new drugs preoperatively in patients with localized breast cancer, using the rate of pathological complete response as the primary end point. The FDA has issued guidanc ...